Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update Record PROCYSBI® Product Sales of $25.8 Million Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million Company to Host Conference Call and Webcast Today at 4:30 p.m. EST NOVATO,...

Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...

Raptor Pharmaceutical Completes Acquisition of Quinsair(TM) NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...

Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...

Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM) First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis Approval Received in the European Union and Canada Expansion of Pipeline with Multiple Late-Stage Orphan Indication...